Last reviewed · How we verify
Bifilact®
Bifilact is a probiotic therapeutic that restores beneficial bacterial flora to treat or prevent gastrointestinal and related disorders.
Bifilact is a probiotic therapeutic that restores beneficial bacterial flora to treat or prevent gastrointestinal and related disorders. Used for Restoration of normal intestinal microbiota in dysbiosis, Gastrointestinal disorders associated with bacterial imbalance.
At a glance
| Generic name | Bifilact® |
|---|---|
| Also known as | probiotics |
| Sponsor | CHU de Quebec-Universite Laval |
| Drug class | Probiotic |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Bifilact contains live Bifidobacterium longum bacteria that colonize the intestinal tract, promoting a healthy microbiome balance. By restoring commensal bacteria, it may reduce pathogenic overgrowth, improve intestinal barrier function, and modulate local and systemic immune responses. This mechanism is intended to address dysbiosis-related conditions and support gastrointestinal health.
Approved indications
- Restoration of normal intestinal microbiota in dysbiosis
- Gastrointestinal disorders associated with bacterial imbalance
Common side effects
- Gastrointestinal disturbance
- Mild abdominal discomfort
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bifilact® CI brief — competitive landscape report
- Bifilact® updates RSS · CI watch RSS
- CHU de Quebec-Universite Laval portfolio CI